# US 2023/0068007 A1 · System and method for discovering drug active site of protein using pathogenic mutation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068007 A1
- Document ID: US20230068007A1
- Status: Published application
- Kind: A1
- Application number: 17/822,899
- Filed: 2022-08-29
- Published: 2023-03-02
- Earliest claimed: 2021-08-30
- Assignees: 3Billon
- Applicants: 3Billon
- Inventors: Jungsul LEE
- Web page: https://patentgrep.com/patent/US20230068007A1

## CPC

- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G16B 15/30: Drug targeting using structural data; Docking or binding prediction
- G16B 15/20: Protein or domain folding
- G16B 20/30: Detection of binding sites or motifs
- G16B 20/50: Mutagenesis
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein is a system for discovering a drug active site of protein using a pathogenic mutation. The system includes: a pathogenic mutation position detection unit for detecting a pathogenic mutation position corresponding to a pathogenic mutation in a three-dimensional structure of protein, using pathogenic mutation data containing information on a pathogenic mutation causing an abnormal protein function and protein structure data containing information on the three-dimensional structure corresponding to genetic sequencing of the protein; and a drug active site detection unit detecting a drug active site, corresponding to the pathogenic mutation position, and, to which a drug is bindable.

## Claims

### Claim 1

A system for discovering a drug active site of protein using a pathogenic mutation comprising:
a pathogenic mutation position detection unit for detecting a pathogenic mutation position corresponding to a pathogenic mutation in a three-dimensional structure of protein, using pathogenic mutation data containing information on a pathogenic mutation causing an abnormal protein function and protein structure data containing information on the three-dimensional structure corresponding to genetic sequencing of the protein; and
a drug active site detection unit detecting a drug active site, corresponding to the pathogenic mutation position, and, to which a drug is bindable.

### Claim 2 (depends on 1)

The system according to claim 1, wherein the drug active site includes at least one among a structure directly exposed externally of the three-dimensional structure of the protein, and a structure exposed externally through a path connected externally of the three-dimensional structure.

### Claim 3 (depends on 1)

The system according to claim 1, wherein the drug active site detection unit detects an empty space, which is adjacent to the pathogenic mutation position in a protein model formed in a three-dimensional structure corresponding to each atom contained in the three-dimensional structure of the protein, has a volume greater than or equal to a predetermined volume corresponding to the drug, and is connected externally of the protein model, as the drug active site.

### Claim 4 (depends on 3)

The system according to claim 3, wherein the three-dimensional structure has a radius at a predetermined ratio of Van der Waals Radius of each atom.

### Claim 5 (depends on 3)

The system according to claim 3, wherein a first coordinate included in the empty space is connected to a second coordinate located outside the protein model through a path spaced apart from the protein model.

### Claim 6

A method for discovering a drug active site of protein using a pathogenic mutation comprising:
a pathogenic mutation position detecting operation of detecting a pathogenic mutation position corresponding to a pathogenic mutation in a three-dimensional structure of protein, using pathogenic mutation data containing information on a pathogenic mutation causing an abnormal protein function and protein structure data containing information on the three-dimensional structure corresponding to genetic sequencing of the protein; and
a drug active site detecting operation of detecting a drug active site, corresponding to the pathogenic mutation position, and, to which a drug is bindable.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the drug active site includes at least one among a structure directly exposed externally of the three-dimensional structure of the protein, and a structure exposed externally through a path connected externally of the three-dimensional structure.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the drug active site detecting operation is to detect an empty space, which is adjacent to the pathogenic mutation position in a protein model formed in a three-dimensional structure corresponding to each atom contained in the three-dimensional structure of the protein, has a volume greater than or equal to a predetermined volume corresponding to the drug, and is connected externally of the protein model, as the drug active site.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the three-dimensional structure has a radius at a predetermined ratio of Van der Waals Radius of each atom.

### Claim 10 (depends on 8)

The method according to claim 8, wherein a first coordinate included in the empty space is connected to a second coordinate located outside the protein model through a path spaced apart from the protein model.
